Metabolic bariatric surgery use declined by 34.1% from 2022 through 2024, whereas GLP-1 prescriptions increased by more than ...

A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was ...

Resolution occurred after stopping dulaglutide, no obvious clues to mechanism ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

Researchers sought to determine whether GLP-1 receptor agonists affected 10-year mortality and recurrence-free survival in patients with breast cancer.

Adding tirzepatide helped patients shed pounds, improved complete skin clearance rates ...

Primary care practitioners serve a critical role in optimizing clinical outcomes for adults with T2DM by evaluating underlying mechanisms, treatment efficacy, medication safety profiles, and ...

A new GLP-1 weight loss drug called survodutide has shown promising results in a phase 3 clinical trial. The drug, which ...

However, Eli Lilly launched its own weight loss pill, orforglipron, marketed as Foundayo, in April. And the company has ...

GLP-1 receptor agonist use remains low in people with multiple sclerosis despite high eligibility rates for diabetes and obesity indications.

GLP-1 RA use is associated with a lower risk of developing Parkinson disease compared with sulfonylurea use in a large cohort study.

HOUSTON -- Patients with polycythemia vera (PV) and a history of treatment with GLP-1 agonists had significantly lower rates of multiple adverse outcomes associated with the disease, a large ...